However, the pace with which many countries suspended the use of the vaccine reflected a brevity regarding its safety and effectiveness, which contrasted sharply with the confidence shown in other vaccines. Germany, France, Italy, Spain and, to a lesser extent, Britain, relying on the vaccine According to the elections.
Participants receiving the vaccine in the trial had no risk of blood clots or related diseases. And a specific finding revealed no cases of venous sinus thrombosis of the brain – blood clots in the brain that can result in dangerous bleeding – which raised some of the most serious concerns in Europe.
Michael Head, a senior research fellow at Global Health at the University of Southampton in the UK, said the results could be a concern not only in Europe but also globally. He said he had received messages in recent days from colleagues in Ghana, hesitating about how to give protection to the vaccinated people who only celebrated the vaccine’s arrival weeks earlier.
“Over the past few weeks due to the slight beating of the AstraZeneca vaccine – and especially in Europe over the last two or two weeks – new data is showing that it is safe and effective, if you want to excuse the phrase, a Nice shot arm, “he said. “The publication of these results is actually quite well-timed, with potential inhibitions around the vaccine.”
The American trial also showed no change in cases of severe neurological problems. The concern arose last summer after two volunteers in the UK trial of AstraZeneca fell ill due to neurological problems. Although those cases forced a seven-week pause in a US clinical study, the researchers eventually concluded that the diseases could not be linked to the vaccine. Nevertheless, the delay was an important factor in why AstraZeneca fell behind three other vaccine manufacturers, which have won emergency authority in the United States.
AstraZeneca said the vaccine worked well across ethnicities and age groups. The vaccine was 80 percent effective in nearly 6,000 trial enrollees over the age of 65 – the conclusion being that there is concern about insufficient clinical trial data on how well the vaccine works in older people. Some countries in a nutshell Limited vaccinations with shots to younger people Data on the rollout of the vaccine in the UK showed that the course was overturned before the vaccine was given strong protection in older people, before being allowed to use it in all age groups.
Even though the vaccine is not used in the United States, obtaining emergency authorization from the FDA – whose rigorous review process is considered a global gold standard – would be an important milestone for AstraZeneca. Some countries that have not yet authorized the vaccine may follow the FDA’s lead.